Monovalent scFv Antibody Fragment for Topical TNF Alpha Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TNF alpha inhibitors, particularly full-length antibodies, are too large to be effectively administered topically for skin diseases like psoriasis and hidradenitis suppurativa, due to their inability to cross the skin stratum corneum and high production costs, limiting their application and accessibility.
Innovation Solution
Development of a humanized, monovalent, and highly potent antibody fragment, such as a single chain variable fragment (scFv), specifically designed to neutralize soluble TNF alpha with an IC50 of less than 50 pM, which is stable, small enough to penetrate tissues, and cost-effective for production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If full-length TNF alpha inhibitors (150 kDa) are used, then high binding potency and therapeutic efficacy are achieved, but the molecules are too large to cross the skin stratum corneum and cannot be administered topically
Solution Approach 1:
The patent divides the full-length antibody (150 kDa) into smaller functional fragments, specifically single-chain variable fragments (scFv) of approximately 25-30 kDa. This segmentation maintains the essential TNF alpha binding capability while reducing molecular size to enable topical penetration through the skin stratum corneum, directly resolving the contradiction between size and topical applicability.
Solution Approach 2:
The invention extracts only the variable regions (VH and VL domains) from the full-length antibody that are responsible for antigen binding, discarding the constant regions that contribute to molecular size but are not essential for TNF alpha neutralization. This extraction creates a minimized scFv fragment that retains therapeutic function while achieving the small size necessary for topical delivery.
2Reliability
If full-length antibodies are used, then high therapeutic potency is achieved, but production costs are excessively high
Solution Approach 1:
The patent extracts only the essential variable domains (VH and VL) required for TNF alpha binding and neutralization, eliminating the expensive-to-produce constant regions and Fc portions. This extraction results in a minimized scFv fragment that maintains high therapeutic potency (IC50 < 50 pM) while significantly reducing production complexity and cost, making the therapy more accessible.
Solution Approach 2:
The scFv fragment is designed as a simplified, shorter-lived molecular entity compared to full-length antibodies. Its reduced structural complexity enables cheaper production through simpler expression systems, and its sufficient in vivo half-life for topical application makes the shorter duration acceptable, achieving cost-effectiveness without sacrificing therapeutic reliability.
3Reliability
If full-length antibodies are used, then high binding affinity is achieved, but the molecules cannot effectively penetrate tissue barriers
Solution Approach 1:
The patent segments the large full-length antibody into a compact scFv fragment containing only the variable domains responsible for antigen recognition. This segmentation reduces molecular dimensions from 150 kDa to approximately 25-30 kDa, enabling effective penetration through tissue barriers and skin stratum corneum while preserving the intact variable regions that maintain high binding affinity for TNF alpha.
Solution Approach 2:
The invention transitions from a large three-dimensional antibody structure to a compact folded domain structure in the scFv fragment. This dimensional reorganization packs the essential binding residues into a smaller spatial envelope, reducing the molecular footprint and enabling penetration through physical barriers while maintaining the three-dimensional binding interface necessary for high affinity interaction with TNF alpha.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody fragment effectively neutralizes TNF alpha with high potency, allowing for potential topical administration and reduced side effects, while minimizing drug quantities and production costs, thereby enhancing treatment accessibility and affordability for patients.
Implementation Method 1
a binding member for TNF alpha... specific for TNF alpha... neutralizes the activity of soluble TNF alpha
Data Source
AI summary
The present invention relates to anti-TNF alpha binding members and in particular to monovalent, high potency TNF alpha-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.